The Shkreli Pill

• Consider Liquidia (LQDA) only as a high-risk, event-driven idea: the speaker sees potential for a return to $100 if it wins its appeal, but that outcome is uncertain.
• The clearest bearish theme is semiconductor supply risk: the speaker was short Micron (MU) and ASML, and flagged SanDisk as vulnerable if Asian supply rises; no price targets were provided.
• The speaker also favored shorting technology over healthcare, citing potential supply pressure and CPU weakness that could affect Dell (DELL), Intel (INTC), and AMD (AMD), though this was a developing thesis rather than a defined trade.
• MongoDB (MDB) was a tentative hold, with a possible re-entry below $351; the speaker expressed hesitation about software stocks and did not favor a larger position.

• Treat LQDA only as a high-risk rebound trade, not a long-term investment: consider staged entries below $30, with $25 cited as a more attractive level, and be prepared for further losses; a bounce toward $35 was speculative.
• The court ruling favors UTHR relative to LQDA, so UTHR may serve as a hedge against LQDA exposure, though no price target was provided.
• For MDB, the discussed $350/$400 call spread can cap both cost and upside, but no expiration or final recommendation was given; avoid selling $340 puts unless prepared to buy shares if the stock falls.

• MongoDB (MDB) is the clearest near-term bullish setup: the speaker saw potential for a move from around $350 to $400 within about a week, though this is speculative and not guaranteed.
• Moderna (MRNA) may offer a short-term momentum rebound after falling about 7% on a Citi downgrade, but no price target or holding period was provided.
• Ginkgo Bioworks (DNA) was flagged as a possible short, but the lack of a supporting thesis or target makes it a high-risk idea to investigate rather than act on directly.

• Consider Bloom Energy (BE) as a way to gain exposure to rising data-center power demand, but verify its ability to build projects at scale amid construction and regulatory hurdles.
• Treat Kodiak Sciences (KOD) as a high-risk, crowded short rather than an actionable bearish trade: the speaker remains skeptical of its drug evidence, but acknowledged that potential $200–$600 million revenue and high short interest could drive further gains.
• Avoid trading Iovance (IOVA) solely on the mixed momentum comments; the stock was described as both likely to climb and overextended, with no price target or clear timeframe.

• MDB is the clearest short-term trade: the speaker expected it to reach $340 intraday after discussing entries around $325; treat this as a trading target, not a long-term valuation.
• QURE remains a cautious bullish watch, but consider re-entering only on a pullback given regulatory-review volatility; no new entry price was specified.
• Avoid chasing IOVA after its sharp rally from about $8 to $13: raised guidance supports the bullish case, but the stock may retrace.
• KOD has a bearish valuation view of $50–$60 or less versus roughly $85, but its rising price and squeeze risk make shorting especially hazardous.

• Wait for Micron (MU)’s upcoming results and company commentary to confirm whether semiconductor demand is weakening; avoid shorting MU or SanDisk (SNDK) before the evidence is clearer.
• Treat the proposed short in AMD as high risk: the bearish case hinges on its ability to compete with NVIDIA, while strong momentum could drive further gains.
• Meta (META)’s AI investment may prove strategically valuable, but the discussion offered no price target—watch for evidence of durable business results before acting.

• The clearest relative-value idea is long Sandisk (SNDK) / short Intel (INTC), based on the view that AI demand supports memory more than Intel; the pair can still lose if either stock moves sharply.
• Kodiak Sciences (KOD) was flagged as a high-risk, event-driven short ahead of Monday’s clinical results, but a positive surprise could trigger a sharp rally—avoid oversized positions.
• AMD has strong momentum but may be due for a pause; the discussion provides no price target or firm entry point, so avoid chasing the recent run.
• Treat all trade views as time-sensitive, especially shorts, and size positions to withstand sudden adverse moves.

• Avoid chasing AMD at an elevated valuation; its AI-driven CPU-demand upside is uncertain, and strong momentum and supply-constrained demand make a short risky—if already short, consider reducing the position rather than adding.
• Treat the reported contract issue behind Oracle’s 5%–7% drop as a near-term catalyst to monitor, not a buy or sell signal; the financial impact and resolution are unclear.
• Be cautious on semiconductor stocks broadly: rising manufacturing output may signal cycle risk, and the discussion offered no clear sector-wide buy.
• Wait for more information before considering Anthropic’s IPO; the speaker would not buy without knowing the offering price.

• Treat short-covering rallies in heavily shorted stocks as volatile trading events, not proof of improving fundamentals; the discussion offers no price targets or clear entry points.
• Expect possible flow-driven pressure on SanDisk (SNDK) and Micron (MU) if hedge funds continue cutting long exposure, but the transcript does not establish either as a buy.
• The speaker intended to short Moderna (MRNA) again, but a short squeeze could sharply lift the stock, making this a high-risk trade without a stated target or timeframe.
• Avoid treating the Micron or Meta (META) options gains cited as typical; options can expire worthless, so keep any options position small.

• Lam Research (LRCX) is the clearest actionable name: the speaker bought about $50,000 of shares, citing its role in semiconductor equipment and storage demand; research its fundamentals before investing.
• Nidec was described as a potential long tied to storage hardware and AI demand, but verify its AI exposure and the valuation metric cited before acting.
• Treat SanDisk (SNDK) cautiously: NVMe flash demand was a bullish theme, but the stock had already surged 7.7% and a short or LRCX/SNDK pair trade was only a speculative trading idea.
• Avoid treating Jaguar Health (JAGX) as a fundamentals-based investment; the discussion characterized it as a highly speculative, squeeze-driven trade.

• Consider SanDisk (SNDK) as a higher-risk AI-storage momentum trade, but keep position sizes modest; no price target was given.
• The clearest bearish thesis is Micron (MU): monitor DRAM prices and capacity additions, as falling prices could pressure earnings, but strong demand could invalidate the short.
• Treat shorts in Intel (INTC), AMD, and SMH as tentative valuation or rotation ideas; the discussion offered no targets or catalysts, and the AMD short was covered.
• Avoid treating the comments on Moderna (MRNA) as a complete short thesis: a larger short was mentioned, but no rationale, catalyst, or target was provided.

• Consider long ASML as the clearest stated semiconductor pick; the speaker preferred it over TSM and LRCX because its chipmaking equipment is difficult to replicate.
• A relative-value trade mentioned was long NVDA / short AMD, reflecting a preference for Nvidia and concern that AMD’s roughly $1 trillion valuation requires exceptionally strong, sustained growth; no target or timeframe was provided.
• Short IONQ was the speaker’s current stance, tied partly to concerns about acquisitions, but the thesis needs further analysis and has no stated price target.
• Treat NVO cautiously after its reported 7–8% decline: the speaker was tempted to buy, but generic Ozempic competition and rival treatments leave the outlook uncertain.

Consider establishing a long position in Ultragenyx Pharmaceutical (RARE) on pullbacks near $13, targeting $30 to $40 over a one-year horizon on drug commercialization and potential acquisition interest from BioMarin (BMRN).

Allocate core tech capital toward liquid large-cap semiconductor leaders like Taiwan Semiconductor (TSM), ASML Holding (ASML), and Lam Research (LRCX) for consistent gains rather than chasing volatile small-cap stocks.

Track international trading data from foreign suppliers like SK Hynix to gain an early directional edge on correlated memory and storage assets.

Look for short-term trading opportunities to fade morning price surges in AI infrastructure and GPU cloud providers like Nebius Group (NBIS) when rallies are driven by already-known industry news.

To protect your capital, limit individual trade sizing to 1% to 2% of your total portfolio so positions can comfortably absorb normal market swings.

Investors should maintain a bullish stance on semiconductor leader Micron Technology (MU), targeting upside price levels between $1,050 and $1,100. Capitalize on the AI infrastructure expansion by purchasing Bloom Energy (BE) to capture data center power demand, while accumulating shares of Meta Platforms (META) on any market pullbacks. Look for short opportunities in IonQ (IONQ) following speculative rallies toward $39 that lack fundamental revenue support. Consider short positions or underweight allocations in Pfizer (PFE) and Nebius Group (NBIS) due to weak pharmaceutical pipelines and uncompetitive cloud pricing moves. Finally, immediately exit or avoid common shares of QCLS (QCLS) to protect capital from severe dilution risks tied to predatory warrants.

Consider establishing a long position in Ultragenyx Pharmaceutical Inc. (RARE), as the stock is deeply undervalued with high expectations for upcoming FDA gene therapy approvals.

Immediately avoid or divest from Quantum Computing Inc. (QCLS) due to toxic financing structures and anti-dilutive warrants that heavily disadvantage common shareholders.

Prepare for a steep decline in Sellas Life Sciences Group (SLS) over the next month ahead of anticipated poor clinical trial outcomes.

Look to trim positions or take profits on Advanced Micro Devices, Inc. (AMD) as it trades near the $150–$155 range, where cost increases from Taiwan Semiconductor Manufacturing Company (TSM) could pressure profit margins.

Treat micro-cap meme coins on platforms like Pump.fun strictly as fast, intraday trading opportunities rather than long-term investments due to extreme liquidity drain risks.